Precision Medicine Unveils New Spatial Biology Solutions
Advanced Solutions Enhance Immuno-Oncology Experiences
Innovative Integration in Spatial Biology
Precision for Medicine, a distinguished leader in drug development and commercialization services, has taken a significant step by integrating Akoya's PhenoCycler-Fusion 2.0 along with the new PhenoCode Discovery IO60 panel into its service portfolio. This advancement allows Precision for Medicine to offer a comprehensive range of services utilizing both the PhenoCycler and PhenoImager platforms. These innovations facilitate a seamless transition from biomarker discovery to practical applications in clinical trials.
Understanding the PhenoCycler-Fusion 2.0 System
The PhenoCycler-Fusion 2.0 represents a cutting-edge spatial biology solution that effectively combines automated fluidics with high-speed imaging capabilities. This next-generation platform produces high-resolution images of numerous biomarkers across tissue sections, paving the way for the simultaneous analysis of hundreds of biomarkers. Such capabilities are essential for gaining deeper insights into tumor biology and exploring immune interactions, ultimately enhancing the advancement of precision medicine by spotlighting pivotal protein drivers and improving immune responses against cancer cells.
Introducing the IO60 Immuno-Oncology Panel
The introduction of the 60-plex IO60 Panel addresses the increasing need for a robust immuno-oncology solution. This innovative panel features an extensive range of fully validated markers integrated into a streamlined workflow. Designed specifically to accommodate immune cell types, key checkpoint inhibitors, tumor microenvironment components, and acknowledged immunotherapy targets, it significantly enhances the efficiency of the research process.
Expert Insights from Precision for Medicine
Darren Davis, PhD, Senior Vice President of Precision for Medicine, expressed enthusiasm about integrating these advanced tools: "By implementing the PhenoCycler-Fusion 2.0 and ready-to-use panels like the IO60 immuno-oncology product from Akoya, we are enhancing our existing spatial biology capabilities. This enhances support for discovery and translational programs, ranging from ultrahigh-plex proteomic findings to low-plex biomarker panels in clinical trials. Understanding immune cell interactions with the tumor environment—a critical aspect of effective therapies—is essential for successful cancer treatment."
Streamlined Workflows and Enhanced Research
The comprehensive capabilities of Precision for Medicine as a CLIA-certified lab, equipped with an expansive biospecimen repository, empower the organization to provide in-house biomarker discovery, assay development, and validation, paired with expedited data delivery. Therefore, researchers reap the benefits of Precision for Medicine's expertise, improving workflow efficiency, ensuring regulatory compliance, and accelerating the path for FDA submissions, culminating in more strategic drug development decisions.
Partnership with Akoya Biosciences
According to Niro Ramachandran, Chief Business Officer of Akoya Biosciences, Precision for Medicine has become one of their strategic CRO partners. "With early access to our innovative spatial biology solutions—such as the PhenoCode Discovery IO60 panel—Precision for Medicine is poised to optimize these solutions for the benefit of their biopharma clients. Akoya’s platforms are leading the spatial biology market from discovery to diagnostics, and partnering with Precision for Medicine allows us to unlock the full potential of our innovations."
Future Outlook and Clinical Implications
The PhenoCycler-Fusion 2.0 platform stands to significantly accelerate clinical trials by accelerating biomarker discovery and facilitating the identification of effective therapies. Offering Akoya's complete suite of spatial biology solutions further solidifies Precision for Medicine’s status as a frontrunner in spatial biology services—a crucial element in advancing precision oncology, immunotherapy, and personalized medicine. Davis further remarked, "Our ability to deliver an all-encompassing, high-plex spatial biology workflow is a pivotal advancement for our biopharma partners, allowing them to leverage innovative proteomic and genomic insights to expedite their biomarker discovery and drug development processes with a single strategic ally."
About Precision for Medicine
Precision for Medicine specializes in biomarker-driven clinical research and development services, expertly supporting life sciences companies in harnessing biomarkers crucial for more precise targeting of patient treatments. Utilizing a transformative approach, Precision integrates clinical trial design with profound scientific insights, laboratory proficiency, data sciences, and advanced manufacturing techniques. The synergy of these elements is driving more rapid clinical development and approval processes. As part of the Precision Medicine Group, which employs 3,400 professionals across 40 locations worldwide, Precision for Medicine is dedicated to advancing innovative research solutions.
Frequently Asked Questions
What is the significance of the PhenoCycler-Fusion 2.0?
The PhenoCycler-Fusion 2.0 allows for ultrahigh-plex and high-throughput analysis of biomarkers, enhancing insights into tumor biology and immune interactions.
How does the IO60 Panel support immuno-oncology research?
The IO60 Panel offers a broad set of validated markers for essential immune processes, streamline workflows, and optimize research efficiency in immuno-oncology.
Who is Precision for Medicine partnered with?
Precision for Medicine collaborates with Akoya Biosciences to enhance its spatial biology offerings, providing tools that are critical for drug discovery and development.
What are the benefits of being a CLIA-certified lab?
As a CLIA-certified lab, Precision for Medicine ensures high standards in laboratory testing and biomarker analysis, enhancing reliability in clinical research.
What does Precision for Medicine aim to achieve?
Precision for Medicine focuses on revolutionizing drug development through advanced biomarker applications, facilitating personalized medicine and effective treatment strategies.
